All News
Ab1012 #ACR22
@AlexisOgdie Opioid Use & Healthcare Utilization in PsA and AS
21% PsA pts on opioids, 27% AS on opioids
Opioid users - more co-morbidities, 🚬, worse disease
Tended to higher use of anti-rheumatic drugs
Higher health care utilizations, medical $$
@RheumNow
Eric Dein ericdeinmd ( View Tweet)
CASIPSA results: CT SIJ characteristics from PsA pts similar to age- and sex-matched controls, but w/ higher prevalence of erosions, found in 18% of PsA patients. Abs 1012 #ACR22 https://t.co/jdUSUoUUbf https://t.co/2NQOhncYFc
Dr. Rachel Tate uptoTate ( View Tweet)
To propose early intervention in pre-clinical PsA we need to first identify pts!
Eder et al. PRESTO Prediction of Psoriatic Arthritis Tool
Dvlped 600+ Pso
M stiff, PASI, nails, fatigue pain severity
Sens 61% Spe 77% for 5% proba PsA onset w/in 5yrs
Abs#1612 #ACR22 @Rheumnow https://t.co/QYOIKe3nui
Aurelie Najm AurelieRheumo ( View Tweet)
Tapryal et al. Diagnostic delay of >6 months contributes to poor PROs in PsA. @RheumNow #ACR22 Abstr#1507 https://t.co/dkaNhXUAeD https://t.co/6G7X7V1aRI
Richard Conway RichardPAConway ( View Tweet)
Karmacharya et al. Multimorbidity in PsO strongly influences incident PsA, >=2 comorbidities HR 2.53, >=5 comorbidities HR 3.19. Also higher for non-white, HR 4.02, and decreased with age. @RheumNow #ACR22 Abstr#1506 https://t.co/OFobRzhQVL https://t.co/IP08XlD66H
Richard Conway RichardPAConway ( View Tweet)
Benesova et al. Higher treatment response to secukinumab in both male and female AS patients when diagnosed earlier. No such effect seen in PsA patients. Emphasises need to reduce diagnostic delay in AS. @RheumNow #ACR22 Abstr#1497 https://t.co/9g2zN85a33 https://t.co/LfvQFTKr69
Richard Conway RichardPAConway ( View Tweet)
Promising results for Izokibep in PsA
Ph2 RCT meets primary endpoint at Wk 16
ACR50: 13% PBO 48% 40mg IZO 52% 80mg IZO
MDA: 5% PBO 42% 40mg 39% 80mg
Results observed as soon as wk2
No new safety signal compared to IL17Ai
https://t.co/Gilhg5k36b
Abs#1597 #ACR22 @RheumNow https://t.co/VvxSRLtkFk
Aurelie Najm AurelieRheumo ( View Tweet)
Abs 1187 apremilast may have beneficial effects on cardiometabolic measures including reductions in HbA1c in severely obese patients and reductions in weight and dz activity improvements in PsO/ PsA outcomes across all BMI categories. #ACR22 @RheumNow https://t.co/fCdJxz2IDk https://t.co/mLnwKQs539
Dr. Rachel Tate uptoTate ( View Tweet)
Baker et al, Corevitas registry in 7000+ RA pts
Pts w/ moderate pain HR 1.37
Pts w/ severe pain HR 1.42
more likely to switch to diff MOA b/tsDMARD
Adjusted for confounders incl DA
Time we address pain separately to spare MAOs in a lifelong disease!
Abs#1590 #ACR22 @Rheumnow https://t.co/RP8Rb6bp9m
Aurelie Najm AurelieRheumo ( View Tweet)
Metabolic disorders +diet patterns PsA
👉71.9% obese
👉metabolic synd 46.9%
👉dyslipid 41.9%
👉 HTN 37.5%
Diet patterns assoc Dx activity
⬇️sugar⬇️fatigue⬇️PSAID score
⬆️whole fruit ⬇️SJC
⬆️unsat fats ⬆️enthesitis
DIPSA -Med/DASH diet PsA ongoing
#ACR22 @RheumNow Abst1007 https://t.co/cbggEw6IZp
Patricia Harkins DrTrishHarkins ( View Tweet)
#abs1601 #acr22 @rheumnow gender analysis of RCT 166 PsA pts on UST: F show ⬇️ response in resolution of pain, enthesitis, dactylitis& ACR response rates in both mono and MTXcombo groups. Unlike M, F seem not to benefit from UST+MTX combo for improvement of enthesitis& dactylitis https://t.co/a0uao6eWDO
Olga Petryna DrPetryna ( View Tweet)
BE COMPLETE study:
Bimekizumab (IL-17A and IL-17F inhibitor) efficacious in phase 3 trial for treatment of PsA. No new safety signals.
Abs#1599 @RheumNow #ACR22 https://t.co/iXj7wSRNeK
Robert B Chao, MD doctorRBC ( View Tweet)
Abs 1507 at #ACR22 demonstrated that even a 6-month delay in PsA dx from symptom onset contributes to worse patient-reported outcomes measures on overall quality of life. @RheumNow https://t.co/qLOwE9rImz https://t.co/nacdjz5pCy
Dr. Rachel Tate uptoTate ( View Tweet)
The likelihood of a patient self-reporting LDA/REM and specificity of MDA score were unaffected by which MDA criteria were met. @DrLauraCoates et al, Abs 1496 #ACR22 @RheumNow https://t.co/xH70swdZZ0 https://t.co/Wct0emTaDt
Dr. Rachel Tate uptoTate ( View Tweet)
#Abs1260 #acr22 @rheumnow #acrbest Clincial&US eval 54 RA &18 PsA pts: Tenderness aasoctd w/radiographic progress in non-swollen jnts in PsA but not in RA. In tender non-swollen jnts in RA pts, baseline erosions& sonographic synovitis had significant impact on radio progression https://t.co/iqWvHiDeq8
Olga Petryna DrPetryna ( View Tweet)
RZB is efficacious in reducing signs and symptoms of PsA in patients, regardless of patterns of joint involvement Abs 1504 #ACR @AlexisOgdie @RheumNow https://t.co/AIEJbqrqBf https://t.co/kyiocs8TmL
Dr. Rachel Tate uptoTate ( View Tweet)
Sonographic enthesitis is assoc'd w/ sonographic synovitis and tenosynovitis in PsA. Abs 1498 #ACR22 @RheumNow https://t.co/tssYZ55iMq https://t.co/C7Dk66rwVA
Dr. Rachel Tate uptoTate ( View Tweet)
Delay in AS dx appeared to be BMI-dependent in female pts and both genders n PsA dx. In contrast to AS, SEC treatment response of early- and late-diagnosed PsA pts did not differ. Abs 1497 #ACR22 @RheumNow https://t.co/LBo3XapAT4 https://t.co/uAcfeiED4F
Dr. Rachel Tate uptoTate ( View Tweet)
#abs1235 #acr22 @rheumnow
articular fibroblast activation in PSO assessed by 68Ga-FAPI-04 PET-CT assoctd w/⬆️ risk of developing PsA. 10 pts assessed: 6/7 pts (85.7%)w/ 68Ga-FAPI-04 uptake at synovio-entheseal sites progressed to PsA. median PsA-free time 207 (160-240)days https://t.co/Y6EHPaDwfh
Olga Petryna DrPetryna ( View Tweet)
PsA pts starting 1st DMARD tx, both early & late initiators experienced dz activity and PRO improvements up to 6 months post-initiation. Better response, including MDA, achieved in pts initiating DMARD tx w/in 1 yr of dx. Abs 1493 #ACRbest #ACR22 @RheumNow https://t.co/a94sZRQ3VF https://t.co/OSUEoChtFf
Dr. Rachel Tate uptoTate ( View Tweet)
